BOC/BOA 2024 | Professor Donglu Zhao: Annual Progress in the Field of Hematologic Oncology in China

BOC/BOA 2024 | Professor Donglu Zhao: Annual Progress in the Field of Hematologic Oncology in China

2025.03.03
From July 5th to 7th, the "2024 Annual Progress Seminar in Clinical Oncology in China (BOC)," hosted by the Chinese Society of Clinical Oncology (CSCO), was held in Guangzhou. The conference invited numerous domestic oncology experts to highlight the "2023 Annual Progress in Clinical Oncology in China" selected by CSCO. Additionally, it focused on the theme of the 2024 ASCO Annual Meeting, "The Art and Science of Cancer Care: From Comfort to Cure," and discussed and interpreted major research presented at ASCO. To gain in-depth insights into the relevant content and trends, "Oncology Frontier - Hematology Frontier" conducted an exclusive interview with Professor Donglu Zhao from the Harbin Institute of Hematology and Oncology, who provided an excellent analysis of these topics.
Focus on Annual Advances in Clinical Oncology Research in the Field of Breast Cancer in China, Multidisciplinary Collaboration Boosts New Drug

Focus on Annual Advances in Clinical Oncology Research in the Field of Breast Cancer in China, Multidisciplinary Collaboration Boosts New Drug

2025.03.03
From July 5-7, 2024, the 2024 China Annual Clinical Oncology Advances Symposium (BOC) and Beast of ASCO® 2024 China (BOC/BOA) were grandly held in Guangzhou. In the field of breast cancer, this conference brought together important research from the Chinese breast cancer field in 2023 and highlighted key advancements from the American Society of Clinical Oncology (ASCO) Annual Meeting. As one of the contributors to the "Annual Advances in Clinical Oncology Research in China," Professor Biyun Wang from Fudan University Shanghai Cancer Center also detailed the ACE-Breast-02 study at this conference, showcasing the rigor and innovation of Chinese research. "Oncology Frontier" interviewed Professor Biyun Wang, and the compilation is presented below.
Professors Bing Chen and Lijuan Chen’s Team: FUMANBA-2 Study Opens New Horizons for Treating High-Risk Newly Diagnosed Multiple Myeloma

Professors Bing Chen and Lijuan Chen’s Team: FUMANBA-2 Study Opens New Horizons for Treating High-Risk Newly Diagnosed Multiple Myeloma

2025.03.03
The 29th Annual Congress of the European Hematology Association (EHA) took place from June 13 to June 16, 2024, in Madrid, Spain. On the afternoon of June 15, local time, Professor Bing Chen from Nanjing Drum Tower Hospital affiliated with Nanjing University Medical School presented the latest data from the FUMANBA-2 study in an oral report at the main venue of the EHA conference, attracting global medical attention. This study, co-led by Professor Bing Chen and Professor Lijuan Chen from Jiangsu Province People's Hospital, utilizes an all-human BCMA-targeted chimeric antigen receptor T-cell (CAR-T) therapy to bring new hope to high-risk newly diagnosed multiple myeloma (NDMM) patients, heralding a new chapter in multiple myeloma treatment. "Oncology Frontier - Hematology Frontier" invited Professor Bing Chen to provide an in-depth interpretation of the study background, design, and results of the FUMANBA-2 study for our readers.
2024 CSCO YOUNG丨Aspiring Towards the Future : Professor Zefei Jiang Discusses the CSCO Youth Expert Committee and the Growth Path for Young Doctors

2024 CSCO YOUNG丨Aspiring Towards the Future : Professor Zefei Jiang Discusses the CSCO Youth Expert Committee and the Growth Path for Young Doctors

2025.03.03
With the rapid development of the medical field, the growth and demeanor of young doctors, as future pillars of healthcare, are highly anticipated. At the mid-year meeting of the Youth Expert Committee of the Chinese Society of Clinical Oncology (CSCO YOUNG) in 2024, Professor Zefei Jiang from the Medical School of Chinese People's Liberation Army General Hospital shared insights on the committee members' demeanor, the crucial role of young doctors within the association, and experiences and advice for young doctors on their growth path. Drawing from his own experiences, Professor Jiang encouraged young doctors to seize opportunities, actively engage in clinical practice and research, and contribute to both personal and societal value. He also offered words of encouragement to students aspiring to enter the medical field, urging them to pursue their dreams and contribute to the advancement of medical science in China.
ASCO 2024 | Biomarkers and Efficacy Analysis of Immunotherapy Combinations for Metastatic Prostate Cancer

ASCO 2024 | Biomarkers and Efficacy Analysis of Immunotherapy Combinations for Metastatic Prostate Cancer

2025.03.03
The efficacy of endocrine therapy in advanced prostate cancer patients is poor, with most ultimately progressing to castration-resistant prostate cancer (CRPC). Although previous single-agent immunotherapies have shown limited success in prostate cancer, recent studies indicate that combination immunotherapies exhibit higher antitumor activity in patients with metastatic CRPC (mCRPC). At the recent ASCO Annual Meeting, a study analyzed the efficacy of different immunotherapy combinations for mCRPC patients and examined potential biomarkers.
Can COVID-19 Vaccination Help Long COVID Symptoms?

Can COVID-19 Vaccination Help Long COVID Symptoms?

2025.03.02
A recent study in The Journal of Infection suggests that SARS-CoV-2 vaccination may accelerate symptom resolution in individuals with ongoing symptomatic COVID-19 (OSC) and post-COVID syndrome (PCS). Using data from the ZOE COVID Symptom Study app, researchers found that vaccinated individuals experienced greater improvement in symptoms like fatigue and brain fog compared to unvaccinated individuals.
New Breakthrough in SARS-CoV-2 Immunotherapy

New Breakthrough in SARS-CoV-2 Immunotherapy

2025.03.02
A recent study published in Emerging Microbes & Infections introduces C10, a pan-SARS-CoV-2 monoclonal antibody (mAb) that offers a novel approach to combating COVID-19. Unlike traditional neutralizing antibodies, C10 targets infected lung epithelial cells and mediates their elimination via NK cell-driven antibody-dependent cellular cytotoxicity (ADCC).